Company news

Share this article:

Drug developer Depomed said it would cut about 25% of its workforce after its lead drug candidate, Gabapentin GR, failed in a late-stage clinical trial. The company had 105 full-time employees as of Dec. 31, according to a filing with the Securities and Exchange Commission.


Forest Laboratories and Microbia announced that they have entered into co-development and co-marketing deal valued at up to $330 million for Microbia's first-in-class compound linaclotide, currently being investigated for the treatment of constipation-predominant irritable bowel syndrome, chronic constipation and other gastrointestinal disorders.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.